Loading organizations...

We deliver personalized medicine for neurodegenerative patients
Synapticure has raised $41.0M across 3 funding rounds.
Key people at Synapticure.
Synapticure was founded in 2019 by Brian Wallach (Founder) and Peter Wallach (Founding CEO, Founder) and Martina de Majo (Founder).
Synapticure has raised $41.0M in total across 3 funding rounds.
Personalized virtual clinical care is finally here for neurodegenerative diseases like Alzheimer's and related Dementias (Cognitive), Parkinson's and Huntington's (Movement), and ALS (Movement).
We provide a novel approach to care in these diseases, centering a patient and caregiver around a coordinator who quarterbacks patients through our full Multi-Disciplinary Care Resources to local aid, PT/OT and home health support. When you leave our clinic, it's not with a handful of paper referrals, but with our coordinators helping you book and find the best physicians, DME, trials, and even cheapest prescriptions. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes.
Synapticure was built by leading patient and caregiver advocates alongside leading clinicians, biotech executives and telemedicine executives to bring the neurodegenerative disease care and treatment experience into the 21st century, and is backed by the leading Venture funds and Angel investors in the remote health and life sciences space.
Synapticure was founded in 2019 by Brian Wallach (Founder) and Peter Wallach (Founding CEO, Founder) and Martina de Majo (Founder).
Synapticure has raised $41.0M in total across 3 funding rounds.
Synapticure's investors include B Capital Group, Amplify Partners, Felicis Ventures, Great Oaks Venture Capital, Slow Ventures, Tencent Holdings, Y Combinator, Joe Greenstein, Kenny Van Zant, Allegion Ventures, Andreessen Horowitz, Bain Capital Life Sciences.
Synapticure is a healthcare company delivering personalized virtual medicine for patients with neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, ALS, and related dementias. It provides expert-led, multidisciplinary care that integrates neurologists, care coordinators, therapists, and mental health support through a virtual platform accessible across all 50 states. Synapticure’s model addresses critical gaps in traditional care by offering fast access to specialists, comprehensive treatment plans, clinical trial enrollment, and ongoing care coordination, significantly improving patient and caregiver experiences. The company serves patients and their families, focusing on improving quality of life and managing complex symptoms through tailored, continuous care[1][2][3][4][5].
Synapticure was founded by a team including patient and caregiver advocates, clinicians, biotech executives, and telemedicine experts, motivated by the unmet needs in neurodegenerative disease care. The idea emerged from the founders’ recognition of the long wait times, fragmented care, and lack of access to cutting-edge treatments faced by patients. Early traction came from building a virtual care model led by specialists like Dr. Eric Anderson, a pioneer in teleneurology, and integrating clinical trials and multidisciplinary support into a seamless patient journey. The company has evolved to partner with leading research organizations and expand access nationwide, particularly targeting underserved and rural communities[1][3][6][8].
Synapticure rides the growing trend of virtual healthcare and personalized medicine, particularly in the neurodegenerative space where traditional care is often fragmented and inaccessible. The timing is critical as new disease-modifying therapies and clinical trials emerge, demanding rapid, expert-led patient access. Market forces such as aging populations, increased prevalence of neurodegenerative diseases, and telehealth adoption favor Synapticure’s model. By bridging clinical care with research and leveraging telemedicine, Synapticure influences the broader ecosystem by setting new standards for integrated, patient-centered neurodegenerative care and expanding trial participation nationwide[1][3][6][8].
Synapticure is poised to expand its impact by deepening clinical trial partnerships, enhancing its virtual care technology, and broadening access to underserved populations. Future trends shaping its journey include advances in neurodegenerative disease treatments, growing demand for remote specialty care, and increasing emphasis on caregiver support. As the company scales, it may become a critical hub connecting patients, clinicians, and researchers, accelerating innovation and improving outcomes in neurodegenerative medicine. Its continued focus on personalized, comprehensive care positions it to transform how these complex diseases are managed in the 21st century[1][6][8].
Key people at Synapticure.
Synapticure has raised $41.0M across 3 funding rounds. Most recently, it raised $25.0M Series A in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $25.0M Series A | B Capital Group | Amplify Partners, Felicis Ventures, Great Oaks Venture Capital, Slow Ventures, Tencent Holdings, Y Combinator, Joe Greenstein, Kenny Van Zant |
| Jan 1, 2022 | $6.0M Seed | Allegion Ventures, Andreessen Horowitz, Bain Capital Life Sciences, B Capital Group, Endeavor Venture Funds, General Atlantic, Joe Kraus, Krishna Yeshwant, GV, Johnson & Johnson Innovation, Red Tree Venture Capital, SV Angel, Triatomic Capital, Trucks Venture Capital, Unusual Ventures, Y Combinator, Ben Silbermann, Frederic Kerrest, George Kurtz | |
| Jul 1, 2021 | $10.0M Seed | Endeavor Venture Funds, Krishna Yeshwant, Triatomic Capital |